论文部分内容阅读
目的探讨早期糖尿病肾病治疗中缬沙坦与前列地尔注射液联合应用的价值。方法选取2016年1月至2017年1月辽阳市中心医院收治的88例早期糖尿病肾病患者作为研究对象,按照1:1比例随机分为研究组(缬沙坦联合前列地尔注射液)与对照组(前列地尔注射液)。比较两组患者治疗效果、尿素氮、血肌酐、微量白蛋白尿排泄率及不良反应发生情况。结果研究组、对照组患者的治疗总有效率分别为93.2%(41/44)、75.0%(33/44),差异有统计学意义(P<0.05);治疗后,研究组患者尿素氮、血肌酐、微量白蛋白尿排泄率水平均优于对照组,差异均有统计学意义(均P<0.05);研究组、对照组患者不良反应发生率分别为4.5%(2/44)、9.1%(4/44),差异无统计学意义(P>0.05),且无1例患者合并两种或以上不良反应。结论在早期糖尿病肾病患者的临床治疗过程中,于常规前列地尔注射液治疗的基础上加用缬沙坦,能获得更为理想的效果,且不会增加不良反应发生风险,安全可靠。
Objective To investigate the value of valsartan and alprostadil injection in the treatment of early diabetic nephropathy. Methods A total of 88 patients with early diabetic nephropathy admitted from Liaoyang Central Hospital from January 2016 to January 2017 were selected and randomly divided into study group (valsartan plus alprostadil) and control Group (Alprostadil injection). The treatment effect, urea nitrogen, serum creatinine, microalbuminuria excretion rate and adverse reactions were compared between the two groups. Results The total effective rates of the study group and the control group were 93.2% (41/44) and 75.0% (33/44), respectively, with statistical significance (P <0.05). After treatment, Serum creatinine and microalbuminuria excretion rate were better than the control group, the differences were statistically significant (all P <0.05); adverse reactions in study group and control group were 4.5% (2/44), 9.1 % (4/44), the difference was not statistically significant (P> 0.05), and no one patients with two or more adverse reactions. Conclusion During the clinical treatment of patients with early diabetic nephropathy, adding valsartan on the basis of conventional alprostadil injection can achieve more satisfactory results without increasing the risk of adverse reactions and being safe and reliable.